In focus · trending topic

Phase 2B PACE

1 stories · following the connections

RespireRx Pharmaceuticals Inc. Announces Publication of Phase 2B PACE Study: Once per Night Treatment with Dronabinol Provides Statistically Significant Improvement in Clinical Measures of Obstructive Sleep Apnea

By Nasdaq OMXNov 30, 2017, 1:45 PM UTC